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Abstract: Neurodegenerative diseases result in a range of conditions depending on the type of
proteinopathy, genes affected or the location of the degeneration in the brain. Proteinopathies such as
senile plaques and neurofibrillary tangles in the brain are prominent features of Alzheimer’s disease
(AD). Autophagy is a highly regulated mechanism of eliminating dysfunctional organelles and
proteins, and plays an important role in removing these pathogenic intracellular protein aggregates,
not only in AD, but also in other neurodegenerative diseases. Activating autophagy is gaining
interest as a potential therapeutic strategy for chronic diseases featuring protein aggregation and
misfolding, including AD. Although autophagy activation is a promising intervention, over-activation
of autophagy in neurodegenerative diseases that display impaired lysosomal clearance may accelerate
pathology, suggesting that the success of any autophagy-based intervention is dependent on lysosomal
clearance being functional. Additionally, the effects of autophagy activation may vary significantly
depending on the physiological state of the cell, especially during proteotoxic stress and ageing.
Growing evidence seems to favour a strategy of enhancing the efficacy of autophagy by preventing
or reversing the impairments of the specific processes that are disrupted. Therefore, it is essential to
understand the underlying causes of the autophagy defect in different neurodegenerative diseases to
explore possible therapeutic approaches. This review will focus on the role of autophagy during stress
and ageing, consequences that are linked to its activation and caveats in modulating this pathway as
a treatment.
Keywords: beta amyloid; autophagy; clearance; toxicity; lysosome; Alzheimer’s disease; ageing;
stress response; apoptosis
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1. Introduction
With ageing, there is a decline in the cell’s ability to maintain protein homeostasis, or proteostasis,
and this natural decline is characteristically exacerbated in all neurodegenerative diseases [1].
Cell survival, growth and proliferation rely on a balance between protein synthesis, folding, trafficking,
aggregation and degradation. The cellular maintenance of proteostasis involves controlling the
conformation, binding interactions, location and concentration of individual proteins making up the
proteome [1]. Protein folding is accomplished through interactions between the folding polypeptide
chain and macromolecular cellular components, including multiple classes of chaperones, folding
enzymes and targeted degradation pathways, which minimize protein aggregation [2]. Human loss
of function diseases are often the result of a disruption to normal proteostasis, typically caused by
mutation in a related gene, thereby compromising the protein folding. In contrast, gain of function
diseases may occur as a result of disrupted proteostasis leading to decreased ability to degrade
misfolded proteins that results in accumulation of toxic protein aggregates, such as beta-amyloid (Aβ)
in Alzheimer’s disease (AD) [3]. Macroautophagy is a bulk-degradation mechanism of autophagy
that is induced by starvation and is important for the clearance of protein aggregates and the removal
of damaged organelles. Macroautophagy aids to indemnify the lack of nutrients by regenerating the
availability of building units non-selectively [4]. However, autophagy can also be highly selective
for damaged organelles and specific proteins and is an important therapeutic approach for protein
misfolding diseases like AD. Autophagy activation is; therefore, an attractive therapeutic strategy
for AD. However, excessive stimulation of this pathway can be detrimental and potentially lethal
to cells with underlying dysfunctional proteostasis. Here, we review the dual role of autophagy as
a protective pathway regulating proteostasis and its pathogenic role in promoting neurodegeneration in
AD. We also discuss whether activation or inhibition of the autophagic pathway has the best potential
as a therapeutic strategy in AD.
2. Autophagy Process
Autophagy can be classified as selective or non-selective. Selective autophagies include mitophagy
(mitochondria), ribophagy (ribosome), lysophagy (lysosomes), pexophagy (peroxisomes), lipophagy
(lipid droplets), glycophagy (glycogen), aggrephagy (misfolded proteins), xenophagy (infected
pathogens) and reticulophagy (endoplasmic reticulum) [5]. Autophagy “cargo” receptor like p62
recognizes specific cargo for autophagic degradation [6]. Conversely, non-selective autophagy
involves the digestion of random parts of the cytoplasm and its components; a process that maintains
proteostasis [7].
Autophagy maintains cellular homeostasis and is usually induced under stress conditions such
as nutrient starvation, the presence of unfolded proteins, viral infection or oxidative stress. Nutrient
signalling is regulated by mTOR (mammalian target of rapamycin) and therapeutic strategies that
involve direct or indirect inhibition of mTOR, such as CCI-779 or Rapamycin. However, deprivation
of amino acids can promote mTOR-independent autophagy proteolysis [8,9]. Deficiency of certain
amino acids can stimulate autophagy but is dependent on cell type and the type of amino acids which
are lacking. Additionally, other factors can affect autophagy such as AMP-activated protein kinase
(AMPK) [10,11] and Bcl-2 (B-cell lymphoma 2) [12].
In brief, the autophagy process involves the formation of an autophagosome, which encapsulates
a section of cytoplasm sequestering misfolded proteins, long-lived proteins, and organelles and
then fuses with lysosomes to enable substrate degradation. Autophagosome formation involves
the initiation of a double membrane organelle called a phagophore that surrounds the cytoplasm
component, including organelles [12], as shown in Figure 1. The autophagosome then fuses with
lysosomes, leading to the hydrolyzation of the inner membrane of the autophagosome and release the
cytoplasm-derived components. Degraded macromolecules are then transported back to the cytosol
to be reused [12]. In selective autophagy, autophagy receptors such as optineurin or p62 recognise
ubiquitinated proteins for degradation via their UBAN (ubiquitin-binding domain in ABIN proteins
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and nemo) or UBA (ubiquitin-associated) domains, respectively, and traffic them to the phagophore [13].
The autophagy receptors then bind to the autophagosomal membrane through an interaction with
light chain 3 (LC3) mediated by an LC3-interacting region (LIR).
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Evidence for the important role of autophagy in maintaining proteostasis in the CNS is
demonstrated by studies showing that autophagy dysfunction contributes to the accumulation
of misfolded proteins, including aggregation of hyper-phosphorylated tau and Aβ leading to
neurodegeneration in AD [14,15]. Inhibition of crucial autophagy genes such as Atg7 or Atg5 lead to
different consequences depending on whether inhibition is complete or selective. Studies showed that
com lete inhibition caused mortality in newborn mice, whil s lective i ibition led to phe otypes
that ar reminiscent of neurodege erative diseases [15]. Inhibition of chape one-m diated aut phagy
(CMA) contributes to the development of ne rofibrillary tangles made up of hyper-phosphorylated
tau proteins. The tau proteins which are bound to lysoso e-associated membrane protein type
2a (LAMP-2A) not only affect lysosomal membranes, but also hinder the mechanism of CMA [16].
Increased levels of regulator of calcineurin 1 (RCAN1) in the brain further demonstrates CMA disruption
in AD [17].
3. Role of Autophagy as a Stress Response Pathway
Eukaryotic cells must adapt continuously to changes in external conditions that induce
stress, including temperat re, ion concentrations, oxygen levels, pH and microbial pathogens.
More importa tly, cells n ed to mai tain intracellular homeostasis by constantly removing unwanted
macromolecules nd cellular waste, accumulation of which is a hallmark featur of AD and many
neurodegenerative diseases. Beyond a certain threshold, such changes beco e “stressors”, meaning
that the cellular response to this stress determines whether the cell can function effectively and survive
(Figure 2). Autophagy constitutes an important protective mechanism that promotes cell survival in
response to multiple stressors and helps defend against degenerative, inflammatory and infectious
diseases [18,19]. Autophagy can be induced by a variety of stress stimuli, including nutrient and energy
stress, proteotoxic stress, pathogen-associated molecular patterns (PAMPs), hypoxia and mitochondrial
damage [20].
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Nutrient depletion or starvation is the most potent physiological inducer of autophagy [21,22].
Several critical molecules regulate starvation-induced autophagy; of these, nutrient signalling pathways
via the kinases mTOR and AMPK are the best characterized. The unfolded protein response (UPR) [23]
is a potent stimulus of autophagy in response to protein aggregation and toxicity. The UPR is mediated
by PERK (PKR-like eIF2a kinase), ATF6 (activating transcription factor-6), and IRE1 (inositol requiring
enzyme 1), all of which are regulated by the chaperone binding immunoglobulin protein (BiP/GRP78).
BiP/GRP78 binds to misfolded proteins, thereby releasing PERK, IRE1, and ATF6 from their inhibitors,
resulting in autophagy activation. Among these, PERK and ATF6 act as autophagy inducers, while IRE1
acts as a negative regulator of autophagy [24].
Microbial infection constitutes a specialized form of cellular stress that results in autophagy
induction [25]. Autophagy activation during infection is regulated by cytokines such as interferon
gamma (IFN-γ) and pathogen recognition receptors (PRRs) that recognize conserved components of
pathogens (PAMPs) [26]. In addition, PRRs recognize PAMPs, necrotic cells, hypoxia, reactive oxygen
species (ROS), and the accu ulation of isfolded proteins. ypoxia (with oxygen concentrations
< 3%) also induces autophagy through a variety of different echanis s. ypoxia-induced autophagy
depends on hypoxia-inducible factor (HIF), while anoxia-induced autophagy is HIF-independent [27,28].
Mitochondrial damage is another potent inducer of autophagy and considerable advances have
been made in understanding the mechanisms by which damaged mitochondria are targeted for
autophagy, and the functional significance of mitochondrial quality control in preventing ageing,
neurodegenerative diseases and other pathologies. Cells clear damaged mitochondria via mitophagy
to prevent the accumulation of ROS. The autophagic recognition of damaged mitochondria is mediated
by the mitochondrial kinase, PINK1 [29], which also plays a critical role in maintaining mitochondrial
integrity [30]. The upregulation of autophagy by these stimuli involves diverse signals that often
have overlapping functions in autophagy, cellular stress responses and cell death pathways, which is
discussed in the next section.
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4. Dual Role of Autophagy: Crosstalk between Autophagy and Apoptosis
Autophagy is constitutively active in the central nervous system (CNS) [31] and helps maintain
homeostasis by eliminating defective proteins and organelles, preventing the accumulation of protein
aggregates, maintaining energy demands, and supporting neuronal plasticity [32,33]. Evidence
indicates that autophagy is neuroprotective [34], which is particularly important in post-mitotic
cells like neurons [13,35]. Neurons have many specialized cell processes for neurotransmission
including axons and synapses that require high energy and protein turnover. Autophagy vesicle
trafficking in neurons can be very lengthy, as autophagosome formation occurs in the distal axon which
undergoes retrograde trafficking to the soma. Therefore, neurons are particularly sensitive to defects in
autophagy-lysosomal trafficking and axonal injuries that induce the accumulation of autophagosomes
or autophagic vesicles (AVs) [36].
Autophagy is closely related to programmed cell death or apoptosis, which is primarily initiated by
mitochondrial membrane permeabilization (MMP) [31]. Selective autophagic removal of depolarized
mitochondria or mitophagy occurs if a small fraction of mitochondria displays MMP. However, beyond
a certain threshold for mitophagy, which varies between cell types and the nature of the stress involved,
MMP constitutes an irreparable and lethal event. It is plausible that liberation of the apoptosis
regulator protein Bcl-2 from activated autophagy protein complexes may free up these molecules to
block pathways of apoptosis [17]. Considering the predominantly cytoprotective role of autophagy,
it seems likely that apoptosis induction would be coupled to autophagy inactivation. For example,
Caspase-3 cleaves Beclin-1, thereby destroying its proautophagic activity. The C-terminal fragment of
Beclin-1 that results from this cleavage acquires a new function and can amplify mitochondrion-mediated
apoptosis [37]. Caspase-3 activation also cleaves and activates Atg4D, an enzyme that catalyses the
delipidation of the LC3 paralog GABARPL1. This proteolytic activation increases Atg4D recruitment to
mitochondria via a putative BH3 domain and enhances its cytotoxic activity [38]. Similarly, the proteolytic
activity of calpain can destroy the proautophagic function of Atg5 [39], generating a proapoptotic
mitochondrion-permeabilizing Atg5 fragment [40].
Although autophagy is generally considered a pro-survival mechanism, autophagy and apoptosis
are interdependent. Autophagy impairment causes an increase in neuronal apoptosis [41]. Autophagy
has been associated with promotion of cell death as a result of excessive activation [42] and also
during cell elimination and neuronal excitotoxicity [43–45]. Some studies have shown that autophagy
inhibition increases neuronal survival in cases such as hypoxic/ischemic brain injury in mice and
necrotic cell death in Caenorhabditis elegans [46–48]. It is likely that excessive autophagy activation
and long-term autophagy up-regulation eventually results in self-digestion [49–51]. The role of
autophagy in cell death and the detailed mechanisms involved are still unclear and it is debated
whether autophagic cell death is apoptosis-related or is a separate process [18,34,52]. Of note, apoptosis
and autophagy have shared regulators, including Beclin-1, Bcl-2, p53, and Atg5, which may interact
to promote neuronal cell death [19,53]. Collectively, these findings underscore that autophagy and
apoptosis are interdependent with multiple shared signalling pathways and regulatory processes.
5. Autophagy and Ageing
Age is the most important risk factor for AD. Ageing is a natural event occurring in all living
organisms, and constitutes a decline in repair processes including autophagy, leading to damage
accumulation and progressive deterioration of cell function. Many organisms show signs of decreased
autophagic capacity with age and growing evidence supports its role as an anti-ageing mechanism.
Decreased autophagy and lysosomal proteolysis during ageing has been extensively reported (reviewed
in [54]). Electron microscopy studies and metabolic assays revealed that rates of proteolysis and
sensitivity to autophagy stimulation decline with age ([55,56]). The regulation of autophagy by
hormones is also differently affected by age ([57]). Lysosomes isolated from different tissues of aged
rodents had reduced ability for binding and uptake of the cytosolic substrate proteins. Interestingly,
the degradation of the substrates was unperturbed by age, suggesting that the activity of the lysosomal
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enzymes is preserved during ageing ([58]. CMA also declines with age. Reduction of LAMP-2A
receptors, which are essential in the mechanism of CMA, is said to affect the rate of proteolysis
and cytoprotective function due to the interruption in the binding of the substrate to the lysosomes.
Furthermore, cholesterol levels in the lysosomal membrane are affected by the level of LAMP-2A
genes [59]. The efficiency of transcription factors linked with autophagy, such as transcription factor
EB (TFEB), also contributes to the decline of autophagy due to ageing [60]. A recent study shows that
overexpression of TFEB results in longevity [59].
Numerous studies involving knockout (KO) or induction of autophagic genes have further
revealed the importance of autophagy in ageing [61]. Atg5 overexpression increased lifespan along
with enhanced autophagy, leanness, insulin sensitivity and motor function in Atg5 transgenic mice [62].
Reducing the decline in levels of LAMP-2A preserved autophagic activity and was associated with
reduced accumulation of damaged proteins and improved organ function in mice [63]. In a nematode
model, Caenorhabditis elegans [64], restoring expression of Atg18 in neurons of Atg18; daf-2 double
mutants fully rescued the shortened lifespan of these animals [65]. Furthermore, several autophagy
transgenic mouse models have an extended lifespan, although the molecular mechanisms behind this
and the connection with ageing are unclear [66]. Tissue-specific ablation of essential Atg genes shows
premature signs of ageing and specific-Atg5 or Atg7 KO leads to neurodegeneration [67]. The level of
expression of certain genes plays a crucial role in the regulation of autophagy and lifespan extension.
Overexpression of sirtuin 1 (SIRT1) activates autophagy, delays ageing and promotes longevity in
both cell and animal models [59]. Furthermore, clinical findings show that serum concentrations of
Beclin-1, a key regulator of autophagy, is associated with longevity in humans [68]. In this study,
healthy centenarians had significantly higher Beclin-1 levels compared with young subjects, suggesting
that elevated basal levels of autophagy may be a biomarker of longevity in humans.
In addition to lifespan extension, studies have also linked autophagy to improved cognitive
functions [69–71]. Many studies have investigated neurodegenerative diseases related to ageing with
autophagy being the main risk factor [72,73]. Most neurodegenerative diseases share the characteristic
of misfolded proteins and damaged organelles, and these accumulations interfere with proper axonal
trafficking, culminating in neurotoxicity. Impairment of either autophagy or CMA hampers the
remodelling of dendrites and axons, thus diminishing neuronal plasticity [74,75]. In AD, extracellular
Aβ plaques secreted by autophagosomes can interrupt intercellular communication [75]. Age-related
decline in memory formation is well established and the above findings support a model in which
a decline in autophagy contributes to the cognitive loss associated with ageing. But the underlying
mechanisms of how autophagy may contribute to brain function during ageing is not well understood.
It is plausible that autophagy is important for many processes in the CNS that contribute to ageing,
including clearance of long-lived and aggregate-prone cytoplasmic proteins and damaged organelles,
to preserve neuronal integrity and promote survival during ageing.
6. Role for Autophagy Genes in AD
Apolipoprotein E4 (ApoE4) is the main genetic risk factor for sporadic AD [74,76]. ApoE4 is
vital for lipid homeostasis, which also extends to autophagy mediated clearance; however, despite
several decades of research, the exact mechanisms underlying its contribution to AD pathogenesis
remain incompletely defined. Genetic risk factors that alter autophagic processes are also implicated
in other neurodegenerative diseases (e.g., Huntington’s disease, amyotrophic lateral sclerosis and
frontotemporal degeneration) [77]. In all of these cases, the lack of efficient degradation by autophagy
leads to the prolonged presence of aggregated proteins that elicit axonal transport malfunction [78].
Mutations within autophagy receptor genes, SQSTM1, OPTN and UBQLN2, and autophagy
regulator genes, VCP and TBK1, are associated with frontotemporal degeneration and amyotrophic
lateral sclerosis [79]. Of these, mutations in SQSTM1 have also been reported in AD cases [80].
Following a meta-analysis that revealed the subgenome-wide association of a SQSTM1 intronic variant
with AD, targeted sequencing was performed on a Flanders-Belgian cohort of patients with either
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early onset AD (EOAD) or a positive family history of AD. A total of 61 SQSTM1 exonic variants
were reported, 57 of which were rare variants. While rare variant burden analysis did not reveal
an increased frequency in patients compared to controls, two common synonymous variants showed
a nominal association with AD [80]. Targeted resequencing of the TBK1 gene in 1253 EOAD patients
and 2117 control individuals revealed 32 rare variants, one of which was a loss-of-function mutation.
Of the 31 missense variants identified, seven were exclusive to patients and four of these had combined
annotation dependent depletion (CADD) Phred scores of >20, which can be indicative of pathogenicity.
However, control-specific and shared variants also attained high (>20) CADD Phred scores and
no enrichment of rare variants in cases compared with controls was observed [81]. There have
been no reports of an association of OPTN or UBQLN2 variants with AD. However, a recent study
identified a variant of unknown significance in VCP in an EOAD patient [82]. Transcript analysis
from the cerebellum and temporal cortex of AD patients highlighted that an OPTN single nucleotide
polymorphism previously associated with Paget’s disease of bone was linked with increased OPTN
expression [83]. Overall, a significant role for autophagy receptor genes or their regulators in AD is
not supported.
A recent review of the gene associations reported in AD highlighted the potential or confirmed
involvement of >40 genes [84] and some of these have roles in autophagy. TREM2 has been shown to
enhance microglial metabolism via regulation of mTOR [85]. Silencing of EPHA1 blocks autophagy [86].
Clusterin, a chaperone involved in proteostasis, is required for pro-survival autophagy [87], LC3
lipidation and autophagosome biogenesis [88]. PICALM modulates autophagy, and subsequently
tau turnover via endocytic trafficking [89]. KAT8 is a histone acetyltransferase, overexpression of
which increases autophagic flux [90]. WWOX (WW domain containing oxidoreductase) suppresses
autophagy via a direct interaction with mTOR that leads to a reduction in Beclin-1, Atg12-Atg5 and
LC3-II levels [91]. Lastly, MAPT/tau has been shown to repress autophagosome-lysosome fusion
by impeding ESCRT-III complex formation and this leads to an accumulation of LC3-II, p62 and
autophagosomes [92].
7. Role of Autophagy in AD Pathogenesis
Senile plaques containing Aβ protein and neurofibrillary tangles (NFTs) composed of the
hyper-phosphorylated tau protein are the pathological hallmarks of AD [93]. Senile Aβ plaques
are specific for AD, whereas NFTs are found in several tauopathies and are a common marker of
neurodegeneration. Aβ is an amyloidogenic protein produced by amyloid precursor protein (APP)
through proteolytic cleavage at the N- and C-termini by β-secretase and γ-secretase, respectively [94].
The number of amino acid residues in Aβ can range from 39 to 43, with Aβ40 being the most
predominant species [95]. However, Aβ42 tends to be the main toxic species and protein component
in senile plaques in the AD brain [96]. In the brain, Aβ42 is present in low levels during normal
physiological conditions. However, in pathological conditions, Aβ42 is present in high concentrations
and adversely affects neuronal function. Aβ42 is highly aggregate prone and can form multiple
isoforms ranging from small oligomers to mature fibrils. Growing evidence shows that soluble
Aβ42 oligomers are the main toxic species, while plaques (which mostly contain insoluble fibrils) are
considered relatively inert, secondary contributors to the onset of cellular dysfunction and sometimes
even a protective mechanism to limit oligomer toxicity [97].
Dysfunctional autophagy is implicated in the disruption of cell signalling pathways [98] and
increased accumulation of Aβ and tau protein aggregates in AD [99,100]. In contrast to normal
ageing, excessive accumulation of autophagy vesicles (AVs, autophagosomes and lysosomes) has
been observed in post-mortem brain of AD patients [101–103], raising the question of whether the
AV accumulation is a result of autophagy dysfunction [102,104] or due to excessive autophagy [105].
Autophagy is regulated by the nutrient signalling kinase AMPK, and its dysregulation is proposed to
contribute to autophagy dysfunction and neurodegeneration in AD [106]. AMPK is a heterotrimeric
protein complex composed of 3 subunits including a non-catalytic regulatory gamma subunit PRKAG2
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(protein kinase AMP-activated non-catalytic subunit gamma 2) that modulates the ability of the kinase
to control autophagy during stress. The PRKAG2 homolog, SNF4Aγ is required for regulation of
developmental and stress-induced autophagy in a fruit fly model of AD [107]. Recent findings from our
group show that expression of the PRKAG2 gene was increased three-fold in AD-hippocampus and the
AD-frontal cortex, and its protein levels positively correlated with Aβ accumulation in the brain [108].
In yeast, we showed that Aβ42 expression activates autophagy and co-expression of SNF4 (PRKAG2
homolog) markedly reduced the levels of Aβ42 aggregates and autophagic activity [109]. Overall,
these findings show that increased autophagy activation and expression of PRKAG2 could be a response
to increased Aβ accumulation in the AD brain. Our studies also suggest that reduced activation of
genes like PRKAG2 maybe an important contributor to Aβ accumulation and neurodegeneration
in AD.
The equilibrium between the formation of new autophagosomes, maturation and clearance of
autophagosomes by lysosomal degradation is known as autophagic flux and is becoming an increasingly
important concept in understanding neurodegenerative disease pathogenesis. The constant presence
of AV’s in neurodegenerative states indicates induction of autophagy [110]. Newly-formed
autophagosomes are usually eliminated in the neurons by fusion with lysosomes to prevent the
build-up of autophagic intermediates, which are not normally found in a healthy brain [111,112].
The clearance of AVs can be obstructed by inhibition of autophagosome–lysosome transport or by
blocking substrate proteolysis, which results in a massive accumulation of AVs in the AD brain
and in PS/APP, a double transgenic model that expresses familial AD mutation in Presenilin-1,
PS1(M146L) [110].
In addition to excessive autophagy, evidence shows impaired maturation or fusion of
autophagosomes with lysosomes or their transport toward the neuronal cell body in AD. Dysfunction
of endosomal–lysosomal trafficking is also observed with accumulation of AVs in post-mortem human
brain and in a mouse model of AD [112,113]. A study in mouse blastocysts has shown that a mutation
in presenilin-1 (PS1) caused lack of Aβ clearance. PS1 is required for lysosomal turnover of autophagic
and endocytic protein substrates, and its deletion caused loss of autophagy function due to impaired
autolysosome acidification and cathepsin activation (cysteine cathepsins are proteases responsible for
proteolytic degradation within the lysosome) [113,114]. Accordingly, enhancing lysosomal cathepsin
activity in an AD mouse model reduced the accumulation of ubiquitinated proteins and other autophagic
substrates within AVs, and decreased extracellular and total brain Aβ deposition. Overall, these studies
suggest that prominent lysosomal dysfunction is present in AD. In AD mouse models, autophagosome
accumulation in dendrites precedes extracellular plaque formation, indicating that autophagy is an early
response and not as an outcome of plaque formation during end-stage disease [115]. Furthermore, APP,
PS1 and other substrates necessary for the generation of Aβ peptides were identified in isolated AVs in
the livers of AD mice [114], suggesting a potential role for AVs in Aβ generation [116]. A study in AD
patients’ mid-frontal cortex grey matter found a reduction of Beclin-1 protein levels. Moreover, in an
AD mouse model, reduction of Beclin-1 expression resulted in increased intraneuronal and extracellular
Aβ accumulation, neuronal abnormalities and neurodegeneration [117], further supporting a role for
inhibited autophagy in AD pathogenesis.
Microglial cells represent the immune system in the CNS. Microglia are located throughout the
brain and spinal cord, accounting for 10–15% of all cells found within the CNS [118]. In addition to
being the initial and primary form of defence mechanism in the brain that scavenges for plaques,
damaged neurons and microbes, microglia are critical for overall brain maintenance and synaptic
pruning during development. The observation of activated microglia around senile plaques in AD
brain is well documented [119,120]. Autophagy in the CNS has been studied mainly in neurons but
remains largely unexplored in other cell types including microglia. Glial cells can internalize Aβ
and are implicated in its clearance [121–124]. Aβ exposure activates astrocytes, an abundant glial
cell, however, chronic exposure may have detrimental consequences by over-activating autophagy,
inducing release of glial inflammatory cytokines and nitric oxide that leads to neuronal and glial cell
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death [125]. A recent study reported changes in glia and autophagy in the hippocampus of AD mice at
different stages of Aβ pathology. Interestingly, changes in microglial morphology were observed before
Aβ plaque deposition and increased autophagy in glial cells was associated with Aβ deposition [126].
Astrocytes around plaques showed increased LC3. Moreover, Iba1 (ionized calcium-binding adaptor
molecule 1), an inflammatory marker was co-localized with ubiquitin or p62 and was exclusively
found in microglia [126]. Overall, these findings show that disturbed autophagy in glia is an early
event that precedes Aβ plaque deposition. Therefore, particular attention to the timing of a possible
intervention should be taken into consideration.
8. Autophagy Therapeutics for AD
Chronic ageing diseases like AD favour the formation of a molecular and cellular environment
that promotes dysfunction in protein degradation mechanisms and, thereby, accumulation of
aggregate-prone proteins such as Aβ and tau. As summarized above, AD exhibits characteristics of
aberrant autophagy which is postulated to be a central pathophysiological factor. The consequences
of autophagic failure are different depending on the stage at which it occurs. It might occur at the
level of autophagosome formation, resulting in accumulation of discarded cargo such as misfolded
proteins and/or dysfunctional organelles [1,31,127], or in the failure to recognize autophagic cargo.
The outcomes; however, may be the same, and depends on the extent of the recognition of dysfunction
and the type of cargo. A third level of defect might arise if the autophagosomes are not properly
cleared, leading to their accumulation. This could interfere with intracellular trafficking and result in
the neuronal loss seen in AD [113].
Modifying autophagy pharmacologically is an attractive approach to prevent or to halt AD by
enhancing the removal of aggregated proteins, thus protecting the cell from dysfunction and death [128].
However, identifying the specific autophagy failure is imperative to the development of therapeutic
strategies [129]. Induction of autophagy reduces the levels of both the soluble and aggregated
species in AD models and is associated with beneficial effects [130–135]. Many autophagy enhancing
molecules have been developed [76,77] and their therapeutic effects have been extensively reviewed
previously [136,137]. Autophagy inducers can be classified into two main groups: mTOR-dependent
or mTOR-independent. mTOR inhibitors are either ATP-competitive inhibitors (e.g., Torin1) or
non-ATP-competitive inhibitors (e.g., rapamycin and rapalogs) [138]. Because of their inhibition of
mTORC1, mTORC2, and, in some cases, phosphoinositide 3-kinase (PI3K) activities, chronic dosing
of ATP-competitive inhibitors of mTOR activity in animals presents significant toxicity issues [138].
However, non-ATP-competitive inhibitors like rapamycin and its analogues have shown benefits as
autophagy inducers in animal models of AD, Parkinson’s disease (PD), Huntington’s disease (HD) and
prion protein (PrP) disease [127,133,139–142]. They have relatively safer profiles due to their non-ATP
competitive mode of action and selectivity for mTORC1 [143], In fact, everolimus, a rapalog, was
recently approved by the Food and Drug Administration (FDA) for the treatment of tuberous sclerosis.
Many mTOR-independent autophagy activators target AMPK. Trehalose, a widely studied
autophagy inducer in neurodegeneration models [66], has been characterized as an AMPK
activator [144]. The molecular targets of trehalose may be GLUT proteins, a family of glucose
transporters whose inhibition results in activation of AMPK [144]. Trehalose dosing in mice has shown
therapeutic effects, concomitant with autophagy induction, in a wide range of neurodegenerative
disease models, including AD, PD, frontotemporal lobar dementia (FTLD), HD, SCA17, PrP and
amyotrophic lateral sclerosis (ALS) [145]. Metformin is another AMPK-dependent autophagy inducer
that has shown beneficial effects in animal models of neurodegeneration including AD, HD, and Lafora
disease [146].
A growing number of autophagy inducers have been identified, that may act on other pathways,
including cyclic AMP (cAMP)/inositol triphosphate (IP3), such as rilmenidine, clonidine, minoxidil
and verapamil [102]. Our group previously demonstrated that a small molecule antihistamine drug,
latrepirdine, activates autophagy and reduces Aβ pathology in yeast and animal models of AD and
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PD [147–149]. More recently, we developed the use of a rapid absorbance-based assay to measure
Aβ42 toxicity in yeast [148]. Here, we showed significant differences in the levels of protection against
Aβ42 toxicity conferred by physiological (nitrogen starvation) and chemical inducers (latrepirdine,
rapamycin and small molecule enhancer of rapamycin 28) of autophagy. In summary, our findings
provide evidence for autophagy induction as a preventative treatment against oligomer Aβ42-mediated
cell death and neurodegeneration in AD.
Autophagic flux is generally defined as a measure of autophagic degradation capacity and is
increasingly considered to be a critically important concept for development of therapies for AD.
However, despite significant advances in measuring different molecular aspects of the autophagic
machinery, it has remained a challenge to measure autophagic flux in a reliable, sensitive and
quantifiable manner. Additionally, it should be noted that autophagosome flux may be different from
substrate clearance flux, since cargo import and degradation in lysosomes can also be facilitated by
other selective pathways like CMA. Additionally, the protein expression levels of the cargo protein
may be affected over time and is possibly dependent on free amino acid generation by lysosomal
degradation. Although interventions such as rapamycin, trehalose and lithium are used in various
disease models, differences in cell types, treatment concentrations and duration make the interpretation
of the effects of these drugs on autophagic flux challenging [150]. For a clear understanding of the
autophagy dysfunction in AD and for development of effective autophagy-based therapies, it is critical
to be able to monitor autophagy activity in real-time and also measure biomarkers that can be applied
in clinical settings to assess the therapeutic efficiency of autophagy modulation. Several methods have
now been developed to reliably measure autophagy in mammalian cells. In summary, this will include
immunoblotting analysis including (1) detection of the conversion of LC3-I (cytosolic form) to LC3-II
(membrane-bound lipidated form) and p62, (2) detection of LC3 turnover by the comparison of two
samples with and without lysosomal inhibitors and microscopy methods, including (3) detection of
autophagosomes and autolysosomes by electron microscopy, (4) detection of GFP-LC3 (or endogenous
LC3) puncta formation assay for counting the average number of punctate structures per cell by
fluorescence microscopy, and (5) detection of the GFP fragment generated by the degradation of
GFP-LC3 inside autolysosomes by immunoblotting with an anti-GFP antibody [151]. Methods for
monitoring autophagy in mammalian cells has improved significantly in the recent decades but still
presents major challenges. Firstly, there is the challenge of quantitatively measuring a dynamic process
and the inherent limitations associated with inferences based on end-point measurements. Secondly,
there has been the challenge of autophagy organelle heterogeneity (i.e., the occurrence of multiple
autophagy derived organelles in different stages of maturation), which makes it very difficult to
examine them accurately.
9. Conclusions
Autophagy plays a key role in maintaining cellular homeostasis and survival by promoting
clearance of mutant/misfolded proteins. Despite significant progress in understanding the molecular
and cellular mechanisms of autophagy, it is still unclear under which circumstances “enhanced
autophagy” plays a role in cell death or represents a rescue mechanism with protective effects.
Furthermore, whether autophagy can cause cell death directly or is a secondary effect of apoptosis
remains to be determined. It should be noted that an increased number of autophagosomes is not
always an indicator of enhanced autophagy. It may also indicate either an accumulation of uncleared
autophagosomes due to impaired fusion with lysosomes, or a dysfunction in one of the various
autophagy induction pathways.
In conclusion, stimulation of autophagy in AD may have potential as a neuroprotective strategy,
as long as excessive stimulation, which can be destructive, is avoided (Figure 3). It is essential to
consider that modifying autophagy may lead to diverse consequences and interfere with mechanisms
that are yet to be unravelled. By revealing the molecular mechanisms involved in autophagy and the
role that this process plays in neuronal survival and death pathways, it should be possible to determine
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whether inhibition or stimulation of autophagy will be of therapeutic benefit in AD. From a therapeutic
perspective, we believe that the evidence overall suggests that autophagy is a promising target.
In addition to clearance of protein aggregates, autophagy upregulation has further protective effects by
reducing the susceptibility to pro-death insults. One benefit of autophagy upregulation as a therapeutic
approach is that constitutive activation of the pathway may not be required, as a targeted strategy to
a particular component may be sufficient to improve autophagy efficacy.Int. J. Mol. Sci. 2020, 21, x FOR PEER REVIEW 11 of 19 
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lysosomal clearance, by regulating the homeostasis of the axon terminal, membrane recycling, 
presynaptic function and removal of neurotoxins. (B) Under pathogenic conditions, as seen in human 
AD brains, autophagy activation can become detrimental in neurons with pre-existing protein 
aggregation and dysfunctional lysosomal clearance. In addition, autophagy activation could 
potentially lead to increased accumulation of immature autophagosomes, impaired autophagosome–
lysosome fusion or may lead to the excessive degradation of essential organelles, self-digestion and 
neuronal death. 
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